Clinical impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy; Japan-Korea Collaborative Research

Clinical impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy - Clinical impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058113

Enrollment

1500

Registered

2025-06-07

Start date

2024-03-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic ductal adenocarcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who underwent pancreatectomy with curative intent between January 1, 2017, and December 31, 2021 2. Patients diagnosed with invasive pancreatic ductal adenocarcinoma 3. Patients who received neoadjuvant therapy prior to curative resection 4. Patients who underwent FDG-PET/CT before curative resection

Exclusion criteria

Exclusion criteria: 1. Patients under 18 years of age at the time of surgery 2. Patients who declined to participate in the study

Design outcomes

Primary

Measure	Time frame
Postoperative Overall Survival	—

Secondary

Measure	Time frame
Recurrence-free survival, Rate of early recurrence, Pattern of recurrence	—

Countries

Japan,Asia(except Japan)

Contacts

Public ContactNaoki Ikenaga

Kyushu University Department of Surgery and Oncology

ikenaga.naoki.533@m.kyushu-u.ac.jp092-642-5441

Outcome results